



**THE STRENGTH OF A KINGDOM**

INVEST IN NAVARRA



BIOMEDICAL COMPANIES

25



RESEARCH CENTRES

5



UNIVERSITIES

2



LEADING HOSPITALS IN NAVARRA

2



DIRECT JOBS

2,400

Navarra has one of the most dynamic biomedical clusters, with fascinating investment opportunities

**Biomedical research**  
Over 100 patents have been registered

Navarra has two prestigious universities with a long-standing academic tradition and a public and private healthcare network linked to the universities and other stakeholders in applied research.



Applied Medical Research Centre  
Universidad de Navarra

Opened in 2004 after 50 years' experience



**Biomedical companies in Navarra**



30 PRIVATE COMPANIES AND RESEARCH CENTRES



2,400 PROFESSIONALS WORKING

Centro de Investigación Médica Aplicada

300 RESEARCHERS OF MORE THAN 20 COUNTRIES

5 PRODUCTS IN PRECLINIC PHASE



22 PATENTS ACTIVE

2 SPIN OFF COMPANIES



**The Government of Navarra is strongly committed to the development and consolidation of the biomedical sector in Navarra**

10 IN THE LAST 10 YEARS THE EVOLUTION HAS BEEN VERY POSITIVE.

APPEARANCE OF NEW TECHNOLOGY-BASED COMPANIES IN NAVARRA.

**Innovation Park, collaborates with**

- ◆ THE ACADEMIC WORLD
- ◆ THE HEALTHCARE SYSTEM
- ◆ THE INDUSTRY



It supports a large infrastructure network, with a public administration that encourages commercial activity.

## Consolidation of an emerging sector

Navarra has one of the most dynamic biomedical clusters in Spain, with great opportunities for investment and partnership in the sector.

**It consists of 25 companies, 5 research centres, 2 universities and 2 leading hospitals in Navarra.** The innovation infrastructure of the region is among the best in Spain, enabling the development of biomedical products from the phase of discovery through to their marketing. Backed by the high level of the healthcare sector and future trends, the biopharmaceutical sector has considerable scientific and technological weight, with strong specialisation in biotechnology and pharmaceutical products.

This is possible thanks to the work done together by companies and institutions in the region.

## Biomedical research in Navarra

Navarra has two prestigious universities, a public and private healthcare system that is closely linked to the universities and other entities that drive applied research - CIMA and NAVARRABIOMED - under the umbrella of the Health Research Institute of Navarra (IDISNA) - and the Institute of Agrobiotechnology (IdAB). The biomedical cluster in Navarra has grown steadily through business initiatives. It consists of more than 30 private companies and research centres that employ more than 2,400 people. Research activity is being extended to new, emerging fields such as Nano biomedical R&D. This activity is mainly focused on L'Urederra and CEMITEC, two public technology centres. More than 100 patents have been registered over the period.

1. CIMA is the biggest biomedical research centre in Spain. It opened in 2004, based on the 50 years' experience of the Faculty of Medicine and the University Hospital of Navarra, and that of the Faculties of Science and Pharmacy and the Applied Pharma-biology Research Centre. It employs over 300 researchers from more than 20 countries and has over 22 patents active and 5 products in the pre-clinical phase. Every year around 10 million euros are invested in basic and applied research.
2. The biomedical cluster of Navarra includes some of the most notable Spanish biomedical companies, e.g.:
  - **CINFA:** the leading company in the sale of generic medicines in Spain.
  - **3P Biopharmaceuticals:** the main supplier of development and manufacturing systems of biotechnological and cell therapy products to third parties.
  - **Idifarma:** an independent company that offers drug development and manufacturing services (CDMO) to the pharmaceutical sector.
  - **PaloBiopharma:** works on discovering new drugs that modulate adenosine receptors and their development.
  - **Albyn Medical:** a pioneer in the development of medical equipment.

## Public support for innovation

The Government of Navarra is strongly committed to the development and consolidation of the biomedical sector in Navarra. The evolution over the last 10 years has been very positive, taking advantage of the pull effect of the biggest generic medicines company in Spain (CINFA) and the ecosystem created around it (3P Biopharmaceutical, Idifarma, Geysler Pharma and Lozys). We would highlight the appearance of new technology-based companies in Navarra.

## Main companies in the sector



**Applied Medical Research Centre Universidad de Navarra** is a biomedical research institution belonging to the Universidad de Navarra. Its mission is to carry out translational research of excellence, based on innovative biological knowledge and finding treatment solutions for patients' needs.



**Navarrabiomed**, a publicly-funded research centre created in 1997 with the aim of promoting biomedical research in the Public Health System of Navarra. It serves as a scientific platform to provide services to healthcare professionals working in the public sector interested in carrying out research. The centre's work contributes to the development of translational research and the results are applied in public-sector hospitals.



**Cinfa**, a pharmaceutical company that develops, produces and markets generic medicines, OTC and orthopaedic products. It is a leading company in the generic medicines market, with a share of 25%. In orthopaedics, its Farmalastic brands in pharmacies has a market share of over 45%. Cinfa heads the sector of medicines that do not require a prescription.



**IDIFARMA** offers CDMO services to the pharmaceutical industry, specialising in high-activity medicines. With an increasingly international vision, it offers a wide range of services from initial formulation testing to the marketing of the product. Its modern installations include a plant for the GMP manufacture of batches in solid form for conventional and high-activity drugs.



Development of new drugs based on the modulation of adenosine receptors; adenosine is a key neurotransmitter and the second messenger in the human body. Among its products is PBF-509, for which it has signed a licencing agreement with the Swiss multinational Novartis, to develop, produce and market a powerful immunotherapy drug against lung cancer, making it one of the most attractive companies on the biotechnology scene in Europe.



**3P Biopharmaceuticals** is a GMP-accredited CMO (contract manufacturing organisation) specialised in the development and manufacture of products for biological and cell therapy, from the viability testing to the commercial phases. 3P develops and produces recombinant proteins of the highest level and quality.



**Geysler Pharma** provides pharmaceutical development services ranging from the initial selection of alternatives until final registration, including obtaining the licence and the supply of the end product.



The first plant to develop, manufacture and package medicines in the shape of sweets in Spain. The new factory, covering 4,300 m<sup>2</sup>, will produce around 250 million units of sweets every year, mainly for throat infections (anaesthetic, antiseptic and anti-inflammatory drugs), marketed both in Spain and abroad.



**Ojer Pharma** is a pharmaceutical company, a spin-off of the Universidad de Navarra, that develops innovative medicines and dermatological products to cover the needs of patients worldwide.



**Albyn Medical** has pioneered the development of innovative medical devices since 1985. Specialists in the design and manufacture of products for Urology, Gynaecology and Gastroenterology.



Encapsulation of active molecules in nanoparticles or polymeric microparticles for the pharmaceutical, veterinary, cosmetics and agrifood sectors. It carries out several of its own lines of research (R&D) in the search for polymeric platforms that lead to patents for high added-value products.



A healthcare technology company that has revolutionised access to and the handling of medical information in healthcare environments through the use of Natural User Interfaces based on optoelectronic devices.



A biotechnology company that provides analyses and studies in the bio-health and environmental fields, using the Zebrafish (Danio rerio). This animal model allows the performance of reliable in vivo trials at a reduced price, in both the adult and embryonic stages.